Literature DB >> 12814673

Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness.

Inger Norderhaug1, Olav Dahl, Per A Høisaeter, Reino Heikkilä, Olbjørn Klepp, Dag Rune Olsen, Ivar S Kristiansen, Håkon Waehre, Truls E Bjerklund Johansen.   

Abstract

OBJECTIVES: Brachytherapy is emerging as a new treatment option for prostate cancer, and is increasingly being used in Europe and North America.
METHODS: A systematic review of studies that compared clinical or cost effectiveness of prostate brachytherapy with radical prostatectomy or external beam radiation for patients with localised prostate cancer.
RESULTS: No randomised controlled trials were identified, but five observational studies with comparable patient groups were included in the review. There were no valid data on overall or disease-free survival. There was no difference in disease-free survival based on PSA as a surrogate measure, or in rates of complications. No cost effectiveness studies were found. Based on Norwegian data, the one-year cost of the three treatment options seem fairly similar, while long term cost data are lacking due to lack of data on long term clinical outcome.
CONCLUSION: The evidence on the clinical effectiveness of therapies for localised prostate cancer is scarce, but the outcome appears to be comparable for radical prostatectomy, external beam radiotherapy and brachytherapy.

Entities:  

Mesh:

Year:  2003        PMID: 12814673     DOI: 10.1016/s0302-2838(03)00187-8

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  8 in total

1.  Feasibility of vibro-acoustography with a quasi-2D ultrasound array transducer for detection and localizing of permanent prostate brachytherapy seeds: a pilot ex vivo study.

Authors:  Mohammad Mehrmohammadi; Azra Alizad; Randall R Kinnick; Brian J Davis; Mostafa Fatemi
Journal:  Med Phys       Date:  2014-09       Impact factor: 4.071

2.  Challenges in the Analysis of Outcomes for Surgical Compared to Radiotherapy Treatment of Prostate Cancer.

Authors:  Scott M Glaser; Ronny Kalash; Dante R Bongiorni; Mark S Roberts; Goundappa K Balasubramani; Bruce L Jacobs; Sushil Beriwal; Dwight E Heron; Joel S Greenberger
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

3.  Evolution of health-related quality of life two to seven years after retropubic radical prostatectomy: evaluation by UCLA prostate cancer index.

Authors:  Aurélien Descazeaud; Marc Zerbib; Matthias D Hofer; Joël Chaskalovic; Bernard Debré; Michaël Peyromaure
Journal:  World J Urol       Date:  2005-09-01       Impact factor: 4.226

4.  Prostate-specific antigen nadir concentration, hypertension and diabetes as risk factors for biochemical failure after permanent 125I seed brachytherapy for prostate cancer.

Authors:  Essi Kovalainen; Markku H Vaarala
Journal:  Mol Clin Oncol       Date:  2016-09-13

5.  [Radical prostatectomy for men aged <56 years with prostate cancer. Cost of illness analysis].

Authors:  K Herkommer; T A Fuchs; R E Hautmann; B G Volkmer
Journal:  Urologe A       Date:  2005-10       Impact factor: 0.639

6.  TGFB1 gene polymorphism Leu10Pro (c.29T>C), prostate cancer incidence and quality of life in patients treated with brachytherapy.

Authors:  Andreas Meyer; Thilo Dörk; Natalia Bogdanova; Maria-Jantje Brinkhaus; Birgitt Wiese; Jörn Hagemann; Jürgen Serth; Michael Bremer; Rolf Baumann; Johann H Karstens; Stefan Machtens
Journal:  World J Urol       Date:  2008-11-28       Impact factor: 4.226

Review 7.  Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review.

Authors:  Virginia Becerra; Mónica Ávila; Jorge Jimenez; Laura Cortes-Sanabria; Yolanda Pardo; Olatz Garin; Angels Pont; Jordi Alonso; Francesc Cots; Montse Ferrer
Journal:  BMC Health Serv Res       Date:  2016-10-03       Impact factor: 2.655

8.  Re-implantation after insufficient primary 125-i permanent prostate brachytherapy.

Authors:  Paul Martin Putora; Ludwig Plasswilm; Wolf Seelentag; Johann Schiefer; Patrick Markart; Hans-Peter Schmid; Daniel Engeler
Journal:  Radiat Oncol       Date:  2013-08-06       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.